Loading...

Recombinant Mouse GM-CSF (carrier-free)

Pricing & Availability
Regulatory Status
RUO
Other Names
Granulocyte/macrophage-colony stimulating factor, CSF-α, Pluripoietin-α, Eosinophil colony stimulating factor (Eo-CSF), Burst promoting activity (BPA)
Ave. Rating
Submit a Review
Product Citations
publications
GM-CSF_Mouse_Recombinant_Protein_BA_031313
FDC-P1 cell proliferation induced by mouse GM-CSF.
  • GM-CSF_Mouse_Recombinant_Protein_BA_031313
    FDC-P1 cell proliferation induced by mouse GM-CSF.
  • Recombinant_Mouse_GM-CSF_CF_012022
    Recombinant mouse GM-CSF induces the proliferation of mouse FDC-P1 cell line in a dose dependent manner. BioLegend’s protein was compared side-by-side to the leading competitor’s equivalent product.
Cat # Size Price Save
576310 2 µg ¥11,700
576302 10 µg ¥29,260
576304 25 µg ¥50,350
576306 100 µg ¥151,640
576308 500 µg ¥396,410
Description

GM-CSF is a hematopoietic factor that is produced by T cells, macrophages, fibroblasts and endothelial cells. This multifunctional cytokine stimulates progenitor cells of neutrophils, eosinophils and macrophages. GM-CSF is also a differentiation and activating factor for granulocytic and monocytic cells.

Product Details
Technical data sheet

Product Details

Source
Mouse GM-CSF, amino acids Ala18-Lys141 (Accession # NM_009969) was expressed in E. coli.
Molecular Mass
The 125 amino acid N-terminal methionylated recombinant protein has a predicted molecular mass of 14.2 kDa. The DTT-reduced protein migrates at approximately 13 kDa and the non-reduced protein migrates at approximately 11kDa by SDS-PAGE.
Purity
Purity is >98%, as determined by Coomassie stained SDS-PAGE.
Formulation
0.22 µm filtered protein solution is in 10mM NaH2PO4, 150mM NaCl, pH 7.2.
Endotoxin Level
Endotoxin level is <0.1 EU/µg (<0.01ng/µg) protein as determined by the LAL method.
Concentration
10 and 25 µg sizes are bottled at 200 µg/mL. 100 µg size and larger sizes are lot-specific and bottled at the concentration indicated on the vial. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & Handling
Unopened vial can be stored between 2°C and 8°C for up to 2 weeks, at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week and stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.
Activity
The ED50 is <0.05 ng/ml, corresponding to a specific activity >2x107 units/mg.
Application

Bioassay
Recommended Usage

Use when high specific biological activity is required.

Application Notes

BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue-ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are verified in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at tech@biolegend.com.

Application References

(PubMed link indicates BioLegend citation)
  1. Ahn J, et al. 2012. PNAS. 109:19386. PubMed
  2. Verhagen J, et al. 2012. PNAS. 110:E221. PubMed
  3. Bretscher P, et al. 2015. EMBO Mol Med. 7:593. PubMed
Product Citations
  1. Lin C, et al. 2020. Cancer Immunol Res. 632:8. PubMed
  2. Kuo PC, et al. 2021. Brain Commun. 3:fcab187. PubMed
  3. Chan L, et al. 2022. Cells. 12: . PubMed
  4. Teplensky MH, et al. 2023. Nat Biomed Eng. :. PubMed
  5. Chan L, et al. 2023. Int J Mol Sci. 24: . PubMed
  6. Li T, et al. 2022. J Leukoc Biol. 112:845. PubMed
  7. Yu H, et al. 2022. Cancer Immunol Res. 10:1095. PubMed
  8. Daradoumis J, et al. 2023. Viruses. 15:. PubMed
  9. Petenkova A, et al. 2023. Nat Commun. 14:2761. PubMed
  10. Rastogi I, et al. 2023. Oncoimmunology. 12:2212550. PubMed
  11. Yang N, et al. 2023. Nat Commun. 14:2898. PubMed
  12. Paris J et al. 2019. Cell Stem Cell. 25(1):137-148 . PubMed
  13. Delvecchio FR, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:1543. PubMed
  14. Ma Q, et al. 2021. Clin Transl Immunology. 10:e1300. PubMed
  15. Bachran C, et al. 2017. Sci Rep.. 10.1038/s41598-017-17948-0. PubMed
  16. Delbridge ARD, et al. 2021. Front Cell Neurosci. 14:592005. PubMed
  17. Xia J, et al. 2020. J Immunol. 205:2077. PubMed
  18. Li Y, et al. 2020. Cell Rep. 30:1753. PubMed
  19. Chowdhury D, et al. 2019. Cell Rep. 27:3873. PubMed
  20. Jin Z, et al. 2020. NPJ Regen Med. 5:19. PubMed
  21. Iwashita H, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  22. Keller CW, et al. 2020. Autophagy. 1:. PubMed
  23. Lin W, et al. 2021. Int J Nanomedicine. 16:2775. PubMed
  24. Hao Q, et al. 2022. Front Immunol. 13:1011922. PubMed
  25. Chen X et al. 2017. Cell stem cell. 21(6):747-760 . PubMed
  26. Snell LM, et al. 2018. Immunity. 49:678. PubMed
  27. Alban TJ, et al. 2020. Front Immunol. 1.285416667. PubMed
  28. Ahn J, et al. 2012. Proc Natl Acad Sci U S A. 109:19386. PubMed
  29. Bretscher P, et al. 2015. EMBO Mol Med. 7:593. PubMed
  30. Woo YD, et al. 2020. J Allergy Clin Immunol. . PubMed
  31. Chen X, et al. 2021. Cell Rep. 37:109991. PubMed
  32. Lajqi T, et al. 2020. Front Immunol. 11:546415. PubMed
  33. Ayala M, et al. 2017. J Cancer Res Clin Oncol. 10.1007/s00432-017-2421-7. PubMed
  34. Becker W, et al. 2021. J Crohns Colitis. 15:1032. PubMed
  35. Tian Y, et al. 2021. Front Immunol. 12:761345. PubMed
  36. Taylor D, et al. 2022. Front Immunol. 13:936129. PubMed
  37. Gogokhia L, et al. 2019. Cell Host Microbe. 25:285. PubMed
  38. Xueyang Yu et al. 2017. Immunity. 47(5):903-912 . PubMed
  39. Ayala M, et al. 2017. Breast Cancer Res Treat. 10.1007/s10549-017-4414-2. PubMed
  40. Stephens WZ, et al. 2021. Cell Rep. 37:109916. PubMed
  41. Cartwright ANR, et al. 2021. Cancer Immunol Res. 9:470. PubMed
  42. Khan A, et al. 2021. Cell Rep Med. 2:100372. PubMed
  43. Moriwaki K, et al. 2021. Mucosal Immunol. Online ahead of print.. PubMed
  44. Markworth JF, et al. 2020. JCI Insight. 5:00. PubMed
  45. Barrera-Avalos C, et al. 2021. iScience. 24:103520. PubMed
  46. Konda P, et al. 2022. Am J Cancer Res. 12:210. PubMed
  47. Jain A, et al. 2020. Nat Immunol. 0.920138889. PubMed
  48. Nakamura K, et al. 2018. Cancer Cell. 33:634. PubMed
  49. Wang Y, et al. 2019. Front Cell Infect Microbiol. 9:286. PubMed

Antigen Details

Structure
cytokine
Distribution

T cells, monocytes/macrophages, fibroblasts, endothelial cells, mast cells

Function
Synergistic with IL-1, IL-3, G-CSF; E21R competitive antagonist for receptor binding; stored in ECM with heparan sulfate proteoglycans
Interaction
Granulocyte/macrophage/erythroid/megakaryocytic progenitors, myeloblasts, monoblasts
Ligand/Receptor
Heterodimer GM-CSFR µ subunit (CDw116); β-subunit (CDw131) in common with IL-3R, IL-5R
Bioactivity
Growth/development granulocyte/macrophage progenitors; differentiates myeloblasts/monoblasts; synergizes with Epo proliferation of erythroid/megakaryocytic progenitors
Cell Type
Embryonic Stem Cells, Hematopoietic stem and progenitors
Biology Area
Cell Biology, Stem Cells
Molecular Family
Cytokines/Chemokines, Growth Factors
Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press San Diego.
2. Demetri G, et al. 1991. Blood 78:2791.
3. Fan D, et al. 1991. In vivo 5:571.
4. Negrin R, et al. 1992. Adv. Pharmacol. 23:263.

Gene ID
12981 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
GM-CSF
Specificity Alt (DOES NOT SHOW ON TDS):
GM-CSF
App Abbreviation (DOES NOT SHOW ON TDS):
BA
UniProt
View information about GM-CSF on UniProt.org

Related FAQs

Why choose BioLegend recombinant proteins?

     • Each lot of product is quality-tested for bioactivity as indicated on the data sheet.
     • Greater than 95% Purity or higher, tested on every lot of product.
     • 100% Satisfaction Guarantee for quality performance, stability, and consistency.
     • Ready-to-use liquid format saves time and reduces challenges associated with reconstitution.
     • Bulk and customization available. Contact us.
     • Learn more about our Recombinant Proteins.

How does the activity of your recombinant proteins compare to competitors?

We quality control each and every lot of recombinant protein. Not only do we check its bioactivity, but we also compare it against other commercially available recombinant proteins. We make sure each recombinant protein’s activity is at least as good as or better than the competition’s. In order to provide you with the best possible product, we ensure that our testing process is rigorous and thorough. If you’re curious and eager to make the switch to BioLegend recombinants, contact your sales representative today!

What is the specific activity or ED50 of my recombinant protein?

The specific activity range of the protein is indicated on the product datasheets. Because the exact activity values on a per unit basis can largely fluctuate depending on a number of factors, including the nature of the assay, cell density, age of cells/passage number, culture media used, and end user technique, the specific activity is best defined as a range and we guarantee the specific activity of all our lots will be within the range indicated on the datasheet. Please note this only applies to recombinants labeled for use in bioassays. ELISA standard recombinant proteins are not recommended for bioassay usage as they are not tested for these applications.

Have your recombinants been tested for stability?

Our testing shows that the recombinant proteins are able to withstand room temperature for a week without losing activity. In addition the recombinant proteins were also found to withstand four cycles of freeze and thaw without losing activity.

Does specific activity of a recombinant protein vary between lots?

Specific activity will vary for each lot and for the type of experiment that is done to validate it, but all passed lots will have activity within the established ED50 range for the product and we guarantee that our products will have lot-to-lot consistency. Please conduct an experiment-specific validation to find the optimal ED50 for your system.

How do you convert activity as an ED50 in ng/ml to a specific activity in Units/mg?

Use formula Specific activity (Units/mg) = 10^6/ ED50 (ng/mL)

Go To Top Version: 5    Revision Date: 08/19/2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account